Avastin for Platinum-Resistant Ovarian Cancer – Details


( Last Updated : August 15, 2016)
Generic Name:
Bevacizumab
Project Status:
Complete
Therapeutic Area:
Platinum Resistant Ovarian Cancer
Manufacturer:
Hoffmann-La -Roche Limited
Brand Name:
Avastin
Project Line:
Reimbursement Review
Project Number:
PC0066-000
NOC Date:

Details


Strength:
25mg/mL
Tumour Type:
Gynecology
Indications:
Platinum-Resistant Ovarian Cancer
Funding Request:
In combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan, for the treatment of patients with platinum-resistant recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer
Review Status:
Complete
Sponsor:
Hoffmann-La -Roche Limited
Submission Date:
Submission Deemed Complete:
Prioritization Requested:
Requested and Not Granted
Stakeholder Input Deadline ‡:
Check-point meeting:
pERC Meeting:
Initial Recommendation Issued:
Feedback Deadline ‡:
Notification to Implement Issued:
Recommendation Type:
Reimburse with clinical criteria and/or conditions
Funding Request:
In combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan, for the treatment of patients with platinum-resistant recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer
pERC Meeting:
Final Recommendation Issued:

Files

‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.